News

Researchers established a multidisciplinary lung cancer clinic in a large, community-based healthcare system and conducted a prospective, comparative-effectiveness study to evaluate patients’ experiences with and outcomes of clinic care.

Study findings suggest that there is a need for tailored patient and oncologist information and education on trastuzumab biosimilars, as well as improved health care communication regarding switching.

PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.

Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.

Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.

A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.

Researchers in China studied 168 patients over three 3 to determine the benefits of tyrosine kinase inhibitor therapy in patient s with ALK-positive locally advanced or metastatic NSCLC.

This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.

Researchers at the University of Michigan applied criteria regarding gene variants that may predispose patients to cancer to determine the proportion of veterans who would benefit from genetic counseling.

A recent systematic review found that the overall number of articles commenting on TLS as an adverse event is sparse and there needs to be more transparency regarding the incidence of TLS when employing newer targeted therapies.